Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于公司监事亲属短线交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a short-swing trading violation by a close relative of the company's supervisor. It details the transaction dates, amounts, legal references, and the company's response and corrective actions. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement about insider trading compliance and corrective measures, fitting the category of Regulatory Filings (RNS). The document length is short (2051 characters), and it is not a report publication announcement or a full report. Therefore, the best classification is Regulatory Filings (RNS).
2021-05-20 Chinese
关于公司董事兼副总经理减持股份的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding the planned reduction of shares held by a company director and vice general manager, Mr. Zeng Kai. It details the number of shares to be reduced, the reasons, the method, and compliance with relevant laws and regulations. The document is focused on insider share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is short and it is not a full financial report or earnings release, nor is it an announcement of a report publication. Therefore, the appropriate classification is Director's Dealing (DIRS).
2021-05-17 Chinese
关于参加2021年广东上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by regulatory bodies. It mentions the date and time of the event and invites investors to participate. The content focuses on investor communication and does not contain financial statements, audit information, or detailed report data. It is not a report itself but an announcement related to investor engagement activities. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-05-14 Chinese
上海荣正投资咨询股份有限公司关于公司调整2021年限制性股票激励计划授予价格事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an independent financial advisor report regarding the adjustment of the 2021 restricted stock incentive plan grant price for the company 健帆生物科技集团股份有限公司. It includes detailed explanations, legal references, approvals from board and supervisory meetings, and financial advisor opinions on the fairness and compliance of the stock incentive plan adjustment. The document is not a general annual or quarterly report, nor is it a simple announcement or certification. It is a standalone advisory report focused on a specific financial incentive plan adjustment, which fits the definition of an Audit Report / Information (AR) as it involves applied accounting principles and financial advisory opinions related to internal corporate financial matters, but is not a full annual report or earnings release. The document length (4658 characters) and content confirm it is a full report, not just an announcement or certification. FY 2021
2021-05-12 Chinese
国浩律师（深圳）事务所关于公司注销部分股票期权的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain stock options under multiple stock option incentive plans of a company. It details the legal basis, approvals, authorizations, and specific circumstances related to the cancellation of stock options. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to corporate governance and stock option plans. It does not announce a report publication nor is it a certification or regulatory filing in the narrow sense. The content fits best under a category related to corporate governance or regulatory filings. Since it is a legal opinion letter concerning stock option cancellations, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-05-12 Chinese
国浩律师（深圳）事务所关于公司调整股票期权激励计划行权价格的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm (国浩律师（深圳）事务所) regarding the adjustment of the exercise price of stock option incentive plans of 健帆生物科技集团股份有限公司. It details the legal review, approvals, and authorizations related to the stock option plans from 2017, 2019, and 2019 second phase, including adjustments due to dividends and capital changes. The document is a formal legal opinion rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or earnings data but focuses on legal compliance and authorization of stock option price adjustments. This type of document fits best under Regulatory Filings (RNS) as it is a legal opinion related to corporate governance and compliance but not a direct financial report or announcement of voting results or management changes.
2021-05-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.